Ist bei Faktor-V-Leiden-Mutation eine lebenslange Antikoagulation erforderlich?

Literatur

• 1 Dahlbäck B. The discovery of activated protein C resistance.  Journal of Thrombosis and Haemostasis. 2003;  1 3-9
• 2 Price D, Ridker P M. Factor V Leiden mutation and the risk for thromboembolic disease: a clinical perspective.  Ann Intern Med. 1997;  127 895-903
• 3 Eichinger S, Weltermann A, Mannhalter C. et al . The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism.  Arch Intern Med. 2002;  162 2357-2360
• 4 Ridker P M, Goldhaber S Z, Danielson E. et al . Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.  N Engl J Med. 2003;  348 1425-1434
• 5 Palareti G, Legnani C, Cosmi B. et al . Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped.  Thromb Haemost. 2002;  87 7-12
• 6 Pötzsch B, Madlener K. Gerinnungskonsil. Georg Thieme-Verlag 2002

Autor